<DOC>
	<DOC>NCT00489905</DOC>
	<brief_summary>The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.</brief_summary>
	<brief_title>Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Prostate cancer patients aged between 5080 who is having or will have ADT. Baseline BMD in between 2 standard deviation (SD) and mean of that among young adults. Patients with renal or liver problems, on calcium or other bisphosphonate therapy within six months before enrolling into the study. Patients who have: Serum creatinine levels &gt;212 Âµmol/L (2.4 mg/dL). Creatinine clearance &lt;50 ml/min. WBC &lt;4.0x109/L, Hgb &lt;10 g/dL, platelets &lt;140x109/L. Patients with known hypersensitivity to bisphosphonates. Patients with history of diseases with influence on bone metabolism, such as Page's disease of bone, primary hyperparathyroidism or osteoporosis.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>bone mineral density</keyword>
</DOC>